Marker Therapeutics 과거 순이익 실적

과거 기준 점검 0/6

Marker Therapeutics은 연평균 28.1%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 25.4%의 비율로 증가했습니다. 매출은 연평균 32.4%의 비율로 증가했습니다.

핵심 정보

28.13%

순이익 성장률

41.85%

주당순이익(EPS) 성장률

Biotechs 산업 성장률	17.04%
매출 성장률	32.44%
자기자본이익률	-72.42%
순이익률	-342.96%
최근 순이익 업데이트	31 Dec 2025

최근 과거 실적 업데이트

Recent updates

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Jan 12

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Oct 04

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Sep 13

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Aug 11

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Jun 17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Mar 04

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Nov 19

Marker Therapeutics: Passing Through A Catalyst Desert

Oct 22

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Aug 17

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

May 04

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Feb 22

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Dec 29

매출 및 비용 세부 내역

Marker Therapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqCM:MRKR 매출, 비용 및 순이익 (USD Millions)
날짜	매출	순이익	일반관리비	연구개발비
31 Dec 25	4	-12	4	12
30 Sep 25	5	-14	4	1
30 Jun 25	5	-15	4	0
31 Mar 25	6	-13	4	0
31 Dec 24	7	-11	4	0
30 Sep 24	5	-10	5	8
30 Jun 24	4	-10	5	0
31 Mar 24	3	-12	7	0
31 Dec 23	3	-14	7	0
30 Sep 23	3	-14	8	0
30 Jun 23	4	-17	10	0
31 Mar 23	4	-14	10	0
31 Dec 22	4	-20	11	0
30 Sep 22	4	-26	13	0
30 Jun 22	3	-33	13	0
31 Mar 22	2	-43	14	0
31 Dec 21	1	-42	13	0
30 Sep 21	0	-41	12	0
30 Jun 21	0	-36	12	0
31 Mar 21	0	-31	11	0
31 Dec 20	0	-29	10	0
30 Sep 20	1	-25	10	0
30 Jun 20	1	-23	10	0
31 Mar 20	0	-23	10	0
31 Dec 19	0	-21	10	0
30 Sep 19	0	-152	25	0
30 Jun 19	0	-151	27	0
31 Mar 19	0	-150	26	-2
31 Dec 18	0	-148	24	0
30 Sep 18	0	-15	8	-4
30 Jun 18	0	-15	7	-2
31 Mar 18	0	-12	7	1
31 Dec 17	0	-11	6	0
30 Sep 17	0	-10	6	4
30 Jun 17	0	-8	5	4
31 Mar 17	0	0	5	4
31 Dec 16	0	-2	5	4
30 Sep 16	0	-3	6	3
30 Jun 16	0	28	5	3
31 Mar 16	0	-38	5	2
31 Dec 15	0	-34	4	2
30 Sep 15	0	-33	2	2
30 Jun 15	0	-63	3	1

양질의 수익: MRKR 은(는) 현재 수익성이 없습니다.

이익 마진 증가: MRKR는 현재 수익성이 없습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: MRKR는 수익성이 없지만 지난 5년 동안 연평균 28.1%의 속도로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없어 지난 1년간 MRKR의 수익 성장률을 5년 평균과 비교할 수 없습니다.

수익 대 산업: MRKR은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(40.2%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: MRKR는 현재 수익성이 없으므로 자본 수익률이 음수(-72.42%)입니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/03/20 17:32
종가	2026/03/20 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 우리의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Marker Therapeutics, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Yun Zhong	Brean Capital Historical (Janney Montgomery)
Leah Rush Cann	Brookline Capital Markets
John Newman	Canaccord Genuity

Marker Therapeutics 과거 순이익 실적

과거 기준 점검 0/6

핵심 정보

최근 과거 실적 업데이트

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

First quarter 2025 earnings released: US$0.40 loss per share (vs US$0.27 loss in 1Q 2024)

Full year 2024 earnings: EPS and revenues miss analyst expectations

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Marker Therapeutics, Inc., Annual General Meeting, May 01, 2026

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Forecast to breakeven in 2028

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

New minor risk - Profitability

Marker Therapeutics, Inc. Appoints Kathryn Penkus Corzo to Board of Directors, Effective November 1, 2025

Marker Therapeutics, Inc. Announces Data from Phase 1 APOLLO Study to Present in Two Posters at 67Th American Society of Hematology Annual Meeting and Exposition

Marker Therapeutics, Inc. Announces First Patient Treated in Off-The-Shelf Program

Marker Therapeutics, Inc. Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Insider recently sold US$148k worth of stock

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Marker Therapeutics Reports That Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

First quarter 2025 earnings released: US$0.40 loss per share (vs US$0.27 loss in 1Q 2024)

Price target decreased by 45% to US$6.00

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2025

Full year 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Marker Therapeutics, Inc. Announces Resignation of John Wilson from the Board of Directors

New minor risk - Shareholder dilution

Insufficient new directors

Marker Therapeutics, Inc. announced that it has received $16.1 million in funding

Marker Therapeutics, Inc. announced that it expects to receive $16.1 million in funding

Marker Therapeutics, Inc. Provides Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics Receives $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas to Support the Investigation of Mt-601 in Patients with Pancreatic Cancer

Marker Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $11.431731 million.

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.47 loss in 2Q 2023)

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.48 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: US$1.59 loss per share (vs US$3.58 loss in FY 2022)

Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

New major risk - Share price stability

Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study

Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse

Second quarter 2023 earnings released: US$0.47 loss per share (vs US$1.11 loss in 2Q 2022)

Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen (Multitaa)-Specific T Cell Product Candidate, Mt-401

Marker Therapeutics, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells After Hypomethylating Agent Administration

Marker Therapeutics, Inc. Reports Pre-Clinical Data of Its MT-601 multiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics, Inc. Appoints Monic Stuart, M.D., as Chief Medical Officer

Consensus revenue estimates increase by 277%

Price target decreased to US$2.17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Resignation of Anthony Kim as Chief Financial Officer, Effective September 30, 2022

Marker Therapeutics Wins $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 Artemis Trial of Mt-401 in Post-Transplant AML

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Nasdaq Grants an Additional 180-Calendar Day Compliance Period to Marker Therapeutics to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 41%

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Marker Therapeutics, Inc. Announces FDA Clearance of IND for Mt-601, the Six-Antigen Targeted T Cell Therapy for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Price target decreased to US$3.63

Marker Therapeutics, Inc., Annual General Meeting, May 24, 2022

Marker Therapeutics, Inc. Announces Frederick Wasserman Will Not Stand for Reelection as Director

Full year 2021 earnings: EPS misses analyst expectations

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Clinical Program Updates and Pipeline Expansion

Price target decreased to US$5.63

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics: Passing Through A Catalyst Desert

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from Russell 3000E Value Index

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Earnings beat expectations, revenue disappoints